Medidata (MDSO) To Be Acquired By Dassault For $5.8 Billion
Zacks Investment Research | Jun 13, 2019 09:23PM ET
Medidata Solutions, Inc. (NASDAQ:MDSO) recently announced that it is getting acquired by French Technology stalwart Dassault Systèmes in an all-cash transaction at a price of $ 92.25 per share, representing an enterprise value of $5.8 billion. The acquisition is expected to close by the end of 2019.
Following the announcement, shares of Medidata inched up 0.1% to close at $91.45 on Jun 13. Investors at Medidata consider this to be strategic since the offer value was at 1.2% premium to the company’s closing price just before the news surfaced. Also, the deal value is higher than Medidata's current market cap of $5.49 billion.
With this acquisition, Dassault Systèmes will reinforce its position as a provider of an end-to-end approach to research and development in the healthcare industry. For investors’ notice Dassault Systèmes is a world leader in 3D design and engineering software, helping bring about sustainable innovation.
Medidata Solutions currently has a Zacks Rank #3 (Hold). You can see industry ’s 3.8% rise. The stock has also performed favorably when compared with the S&P 500 index’s 4.9% increase.
How Will the Industry Gain?
Medidata Solutions’ market-leading clinical cloud solutions are used by customers to develop therapeutic innovation. They also complement Dassault’s healthcare solutions on its flagship 3DEXPERIENCE collaborative platform.
Through this acquisition, the healthcare industry will benefit from Medidata’s flagship platforms, thereby boosting drug research and discovery, development, clinical testing, manufacturing and commercialization.
Major U.S. Healthcare M&A Making Waves
Mergers and acquisitions have been the key driver of the U.S. healthcare space lately. Value-based reimbursement, shrinking hospital margins and record-high healthcare spending are pushing providers to consider new partnerships to achieve efficiency and cost control.
Recently, leading DNA sequencing company Illumina (NASDAQ:ILMN) announced the signing of an acquisition agreement to buy its fellow genomics company, Pacific Biosciences of California.
Also, in the recent past, MedTech bigwig Becton, Dickinson and Company’s acquisition of C. R. Bard and JOHNSON & JOHNSON’s (NYSE:JNJ) buyout of Actelion deserve a mention.
A Key Pick
A better-ranked stock in the broader medical space is DENTSPLY SIRONA (NASDAQ:XRAY) , carrying a Zacks Rank #2 (Buy).
DENTSPLY’s long-term earnings growth rate is expected at 11.5%.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.